MoonLake Immunotherapeutics (MLTX)

Executive Summary

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab, a novel trivalent Nanobody® that simultaneously inhibits IL-17A and IL-17F. The company focuses on inflammatory skin and rheumatic diseases with high unmet need, particularly hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). Trading publicly on NASDAQ (MLTX) at a valuation of ~$1.2 billion, MoonLake's lead candidate has demonstrated promising Phase 2 results, showing superiority over placebo and adalimumab in HS. Currently, multiple Phase 3 trials are ongoing in both HS and PsA, with the first HS pivotal trials (MIRA, NCT06411379/NCT06411899) expected to read out in mid-2026. The nanobody platform, licensed from Ablynx (Sanofi), offers potential advantages in dosing, tissue penetration, and dual blockade. With a strong cash position and no approved products yet, MoonLake represents a high-risk, high-reward investment opportunity in the immunology space, dependent on successful Phase 3 data and subsequent regulatory approval.

Upcoming Catalysts (preview)

• Q3 2026Hidradenitis Suppurativa Phase 3 Topline Results (MIRA trials)70% success
• H2 2027Psoriatic Arthritis Phase 3 Interim Analysis or Topline Data65% success
• 2026Potential Partnership or Licensing Deal for Sonelokimab40% success